Cytotoxic effects of palladium(II) and platinum(II) complexes with OjO′-dialkyl esters of (S,S)-ethylenediamineN,N′-di-2-(4-methyl) pentanoic acid on human colon cancer cell lines

Journal of B.U.ON.

Volumn 18, Issue 1, 2013, Pages 131-137

  Volarevic, V ^a   Vujic, J M ^b   Milovanovic, M ^a   Kanjevac, T ^a   Volarevic, A ^a   Trifunovic, S R ^b   Arsenijevic, Nebojsa ^a  

^a University of Kragujevac Medical Faculty   (Serbia)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Cytotoxic effects; Human colon cancer cell lines; Palladium(II) complexes; Platinum(II) complexes

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETHYLENEDIAMINE N,N' DI 2 (4 METHYL) PENTANOIC ACID; PALLADIUM COMPLEX; PLATINUM COMPLEX; UNCLASSIFIED DRUG; VALERIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50;

EID: 84879014529     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Susman S, Tomuleasa C, Soritau O et al. The colorectal cancer stem-like cell hypothesis: a pathologist's point of view. J BUON 2012;17:230-236.
2. Jain KK. Recent advances in clinical oncoproteomics. J BUON 2007;12 (Suppl 1):S31-38. (Pubitemid 350200859)
3. Konstantopoulou I, Pertesi M, Fostira F, Grivas A, Yannoukakos D. Hereditary cancer predisposition syndromes and preimplantation genetic diagnosis: where are we now? J BUON 2009; 14 (Suppl 1):S 187-192.
4. Klein B, Gottfried M. Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab. J BUON 2007;12 (Suppl 1):S127-136. (Pubitemid 350200871)
5. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003;10:1663-1682.
6. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. (Pubitemid 46137553)
7. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7: 573-584. (Pubitemid 47106628)
8. Viale M, Minetti S, Ottone M, Lerza R, Parodi B, Pannacciulli I. Preclinical in vitro evaluation of hematotoxicity of the cisplatin-procaine complex DJPR. Anticancer Drugs 2003;14:163-166. (Pubitemid 36269755)
9. Coluccia M, Natile G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med Chem 2007;7:111-123. (Pubitemid 46062408)
10. Sabo TJ, Kaludjerović GN, Grgurić-Śipka SR, Heinemann FW, Trifunović SR. Complex compounds of platinum (IV) and O,O-dialkyl-ethylenediamineN,N′-di-3-propaonate ligands. A structural evidence for geometry of hydrolytic pro-duct of some esters. Inorg Chem Comm 2004; 7:241-244.
11. Kaluderović GN, Dinovič VM, Juranič ZD, Stanojković TP, Sabo TJ. Activity of some platinum(II/IV) complexes with O,O-n-butyl-and O,O-n-pentyl-ethylenediamine-N,N′-di3-propanoate and halogeno ligands against HeLa and K562 cell lines and human PBMC. J Inorg Biochem 2005;99:488-496. (Pubitemid 40038322)
12. Zmejkovski BB, Kaluderović GN, Gómez-Ruiz S et al. Palladium(II) complexes with R2edda-derived ligands. Part II. Synthesis, characterization and in vitro antitumoral studies of R2eddip esters and palladium(II) complexes. Eur J Med Chem 2009;44:3452-3458.
13. Krajcinović BB, Kaluderović GN, Steinborn D et al. Synthesis and in vitro antitumoral activity of novel O,O′-di-2-alkyl(S,S)- ethylenediamine-N,N′-di-2-propanoate ligands and corresponding platinum(II/IV) complexes. J Inorg Biochem 2008;102:892-900.
14. Vujić JM, Cvijović M, Kaluderović GN et al. Palladium(II) complexes with R(2)edda derived ligands. Part IV. O,O′-dialkyl esters of (S,S)-ethylenediamine-N,N′-di-2-(4-methyl) pentanoic acid dihydrochloride and their palladium(II) complexes: synthesis, characterization and in vitro antitumoral activity against chronic lymphocytic leukemia (CLL) cells. Eur J Med Chem 2010;45:3601-3606.
15. Vujić JM, KaluCrossed d signerović GN, Milovanović M et al. Stereospecific ligands and their complexes. Part VII. Synthesis, characterization and in vitro antitumoral activity of platinum(II) complexes with O.O′-dialkyl esters of (S,S)-ethylenediamine-N,N′-di-2-(4- methyl)pentanoic acid. Eur J Med Chem 2011;46:4559-4565.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63. (Pubitemid 14203433)
17. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989;96:736-749. (Pubitemid 19057595)
18. Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle 2011;10:2380-2389.
19. Yousef I, Bréard J, SidAhmed-Adrar N et al. Infrared spectral signatures of CDCP1-induced effects in colon carcinoma cells. Analyst 2011;136:5162-5168.
20. Lazić JM, Vucićević L, Grgurić-Sipka S et al. Synthesis and in vitro anticancer activity of octahedral platinum(IV) complexes with cyclohexyl-functionalized ethylenediamine-N,N′-diacetate-type ligands. Chem Med Chem 2010;5:881-889.
21. Kaluderović GN, Kommera H, Schwieger S et al. Synthesis, characterization, in vitro antitumoral investigations and interaction with plasmid pBR322 DNA of R2eddp-platinum(IV) complexes (R = Et, n-Pr). Dalton Trans 2009;48:10720-10726.